HoneyBear Biosciences Gets Gold: First to Publish ARC Research in Asia & Wins ‘Best ADC Developer in Taiwan’ at 2025 ABEA

On March 12, 2025, HoneyBear Biosciences Inc. (HoneyBear) received the ‘Best ADC Developer in Taiwan’ award at the Asia-Pacific Biopharma Excellence Awards (ABEA), recognizing its contributions to ADC development in the region. The award was presented during a ceremony at the ADC Asia Congress 2025 in Singapore, where HoneyBear also showcased its proprietary CoNectar™ technology platform in a keynote session. Holding multiple patents for the platform, the company continues to gain recognition among international experts, further strengthening its position in the global antibody-drug conjugate (ADC) industry.

HoneyBear Biosciences Showcases CoNectar™ Technology and Wins Industry Recognition at ADC Asia Congress 2025

HoneyBear Biosciences strengthened its global presence at the ADC Asia Congress 2025 by presenting its proprietary CoNectar™ technology platform. Founded in 2021 and based in Taiwan, HoneyBear focuses on developing novel therapeutics for cancer using its CoNectar™ antibody-drug conjugation platform, for which the company holds multiple patents. As a result, HoneyBear has gained increasing recognition for its contributions to ADC research. The company targets the global pharmaceutical market and collaborates with biotech and pharmaceutical companies through licensing and co-development partnerships to advance Antibody-Drug Conjugates (ADC) therapies.

The ADC Asia Congress 2025 brought together over 40 industry experts and more than 300 attendees from across the Asia-Pacific region, including Singapore, China, Japan, South Korea, and Australia. The event addressed the latest technological advancements and clinical developments in ADCs, with a focus on overcoming industry challenges such as development costs and manufacturing complexities. Presentations also covered emerging trends, new technologies, real-world applications, and recent R&D findings, reflecting the industry’s response to rising global cancer rates and the demand for advanced therapies, fueled by increasing investments and FDA approvals.

Industry Leaders Address Challenges and Innovations in Next-Generation Antibody Drug Conjugates

During the congress, HoneyBear had the opportunity to showcase its CoNectar™ platform, which offers greater diversity and flexibility in drug development. CEO Dr. Simon Shih-Hsien Chuang delivered a keynote speech, presenting new findings from an animal study on Antibody Radionuclide Conjugates (ARC), marking the first time such data had been introduced in Asia. These findings demonstrated how the CoNectar™ platform can enhance ADC development, providing better control over drug dosage, efficacy, and safety. The research indicates that ADCs developed with CoNectar™ could outperform current market-approved ADCs and those in development, potentially offering breakthrough treatments for hard-to-treat cancers. Beyond oncology, the platform may also have future applications in other clinical treatments.

Dr. Chuang emphasized the importance of translating these findings into real-world applications. He outlined HoneyBear’s strategy to expand its product pipeline and accelerate drug development through technology licensing. The company plans to leverage CoNectar™ to create next-generation ADC therapies that offer more targeted and effective cancer treatments.

HoneyBear Recognized for Excellence at ABEA Awards and Highlights Future Growth Plans

Following the congress, Dr. Chuang and HoneyBear’s Vice Chairwoman, Sarina Lin, attended the Asia-Pacific Biopharma Excellence Awards (ABEA) ceremony. The awards, organized to recognize achievements in ADC development across the Asia-Pacific region, span research, design, bioprocessing, supply chain management, and clinical trials. These biopharma awards aim to promote innovation in the field and advance treatment options. At the ceremony, HoneyBear received the ‘Best ADC Developer in Taiwan’ award, which acknowledged its leadership in ADC innovation. This recognition highlighted the company’s ongoing contributions to advancing ADC research and development in the Asia-Pacific region.

In her remarks at the awards ceremony, Sarina Lin emphasized the company’s rapid growth. “HoneyBear is a rising star in the biotech industry. We’ve just completed the fundraising in November 2024, receiving high recognition and substantial investments from venture capital firms and investors,” she said. “Our R&D team and our professional leadership team, with expertise in drug manufacturing, business management, and marketing, ensure the company is managed by an A team so HoneyBear’s performance will be even more noticeable thereafter.”

Looking ahead, Sarina added, “In the future, we will continue to focus on R&D and plan to complete the first Investigational New Drug (IND) clinical trial application by 2026, officially joining the ranks of new drug development.” She concluded, “As we’re continuously and rapidly demonstrating excellent results, we believe more investments will flow in to reinforce the company’s operational efficiency and support HoneyBear in getting exposure in the global market.”

The ABEA win, along with HoneyBear’s active participation in the congress, demonstrates the company’s increasing influence within the global biopharmaceutical industry. As HoneyBear continues to push the limits of ADC technology, it remains focused on developing novel therapeutic solutions and driving progress in targeted cancer treatment.

Dr. Chuang, Simon, Shih-Hsien, CEO of HoneyBear Biosciences, invited to Singapore to give a keynote speech at the ADC Congress Asia on March 12th, 2025. Image: HoneyBear Biosciences Inc.

Related posts:

2023 Taiwan Healthcare Expo: Showcasing Innovative Advances in Biomedical Technology AI-Driven Breakthroughs in Drug Discovery and Treatment Optimization CDMO Samsung Bio Secures Record $1.24 Billion Biopharma Manufacturing Contract, Raising Total 2024 Deal Value to Over $3.3 Billion Driving Post-Pandemic Growth: Navigating Pricing Pressures and the Rise of Generative AI

Author

GeneOnline